Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Unified Patent Court
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
The founding partner of Bird & Bird’s Dutch office explores his recent victory for Edwards Lifesciences and his active role at the court.   19 September 2024
Unified Patent Court visualised: Cases, divisions, and classes in charts
Unified Patent Court
Unified Patent Court visualised: Cases, divisions, and classes in charts
Data visualisations based on the court’s activity from June to August reveal that the use of English is growing, German divisions are dominating, and appeals are creeping up, writes Marisa Woutersen.   12 September 2024
HLK adds CRISPR specialist as partner
Careers
HLK adds CRISPR specialist as partner
CRISPR expert with two decades of experience in biotechnology and life sciences, joins HLK as a partner | Latest addition previously held leadership roles at Murgitroyd and HGF | Partner will be attending LSPN North America Fall 2024 in San Francisco.   10 September 2024
Americas
AstraZeneca unit draws line under Samsung dispute
AstraZeneca unit and Samsung Bioepis resolve their patent dispute over a biosimilar | Settlement follows FDA approval for the generic drug in July 2024 | Agreement dismisses ongoing litigation and appeals, including a federal lawsuit and related patent reviews.   5 September 2024
Careers
Brown Rudnick expands with new partner duo
Firm adds pair to its Washington DC office | Both bring experience in patent counselling and IP transactions | Expertise in biotech, life sciences, pharmaceutical sectors, consumer products, biomedical, chemical, food science, agriculture, and medical devices.   5 September 2024
Careers
Morgan Lewis adds two partners to London office
Firm welcomes veteran litigator from Baker McKenzie and transactional lawyer from Covington & Burling | Pair specialise in global IP litigation and strategic transactions.   3 September 2024
Americas
Regeneron targets almost 50 patents in suit against Sandoz
Regeneron accused the Swiss pharma company of infringing a slew of patents related to Eylea and violating the BPCIA | Suit alleges that Sandoz failed to provide critical information during the approval process for its newly FDA-approved biosimilar | Sandoz “forced” Regeneron to guess which patents might be infringed.   29 August 2024
Careers
High-tech expert joins White & Case in US expansion plan
Former Mayer Brown partner joins White & Case, bringing experience with high-tech companies | New hire specialisms include medical devices, pharmaceuticals and chemical products.   29 August 2024
Americas
Court recommends $54m judgment in Abbott TM case
Federal magistrate proposes awarding Abbott millions of dollars from 85 companies and individuals for selling unauthorised diabetes test strips | Judge advises a permanent injunction in almost a decade old trademark case.   27 August 2024
Americas
FTC endorses greater access to affordable biosimilars
FTC backs FDA's proposals to streamline approval process for interchangeable biosimilars | Move aims to lower prescription drug costs and expand access to critical treatments | FTC emphasises the new guidance could create competition in the biologics market and save US healthcare billions of dollars.   22 August 2024

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.